Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
![The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]](/images/banners/nsclc.gif "The NSCLCs account for 80% of all lung cancers and can be further subdivided into squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma (which includes bronchioloalveolar-cell carcinoma [BAC]")
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Oestrogens / progestogens. |
| Generic Name : | Estradiol [oestradiol], dydrogesterone |
| Presentation : | Femoston 1/10: Estradiol 1 mg (14 white tablets); estradiol 1 mg , dydrogesterone 10 mg (14 grey tablets). Femoston 2/10: Estradiol 2 mg (14 orange tablets); estradiol 2 mg , dydrogesterone 10 mg (14 yellow tablets). Femoston 2/20: Estradiol 2 mg (14 orange tablets); estradiol 2 mg , dydrogesterone 20 mg (14 blue tablets). |
| Indications : | Femoston 1/10: Relief of menopausal symptoms in women with a uterus. Femoston 2/10, Femoston 2/20: Relief of menopausal symptoms. Prevention of osteoporosis. |
| Adult Dosage : | Femoston 1/10: Initially 1 Femoston 1/10 daily without break starting with white tablets. Start by fifth day of menstruation if present or at any time if not. If control of symptoms is not achieved, change to Femoston 2/10. Should rare breakthrough bleeding or inadequate progestational response occur, change to Femoston 2/20. Femoston 2/10, Femoston 2/20: 1 Femoston 2/10 daily without break starting with orange tabs. Start by fifth day of menstruation if present or at any time if not. Should rare breakthrough bleeding or inadequate progestational response occur, change to Femoston 2/20. |
| Child Dosage : | Not applicable. |
| Contra Indications : | Cancer of breast, genital tract or other oestrogen-dependent bleeding. Active deep vein thrombosis, thromboembolic disorders or a history of confirmed venous thromboembolism. Acute or chronic liver disease. Dubin-Johnson or Rotor syndromes. Pregnancy, lactation. Cerebral vascular accident. |
| Special Precautions : | A thorough examination is required before commencing therapy and at regular intervals thereafter. In cases of continuing abnormal and/or irregular bleeding, a diagnostic endometrial biopsy should be performed. Women of child bearing potential should use non-hormonal contraceptive methods. HRT is associated with an increased risk of venous thromboembolism (VTE). If risk factors present (personal or family history, severe obesity), weigh benefits against risks. An increased risk of being diagnosed with breast cancer has been reported with HRT. Monitor patients with epilepsy, migraine, diabetes, cardiac failure, multiple sclerosis, hypertension, porphyria, haemoglobinopathies, otosclerosis, a history of liver disease, uterine fibroids or history of endometriosis. |
| Interactions : | Liver enzyme inducing drugs. |
| Adverse Reactions : | Nausea, breast tenderness, abdominal pain, dysmenorrhoea, bloating, oedema, nausea, skin reactions, haemoglobinopathies, headache, dizziness. REASONS FOR IMMEDIATE DISCONTINUATION OF TREATMENT: Occurence of migraine-type headaches for the first time, frequent severe headaches, acute visual disturbances, signs of thrombophlebitis or thromboembolism, or any other possible prodromal symptoms of vascular occlusion. Rise in blood pressure. Jaundice. Pregnancy. Discontinue four weeks before major elective surgery and during immobilisation entailing risk of thrombosis. |
| Manufacturer : | Solvay |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org